ctcbio Inc.

We are seeking a healthy future through continuous research and innovation. **For medical and healthcare:** We have developed CDFR0812-15/50mg, a combination drug for the treatment of premature ejaculation and erectile dysfunction, which has been approved by the KFDA. This is the world’s first combination therapy, offering a new treatment option. As a leader in Orally Disintegrating Film (ODF) manufacturing technology, we have developed innovative formulation technologies that enable convenient administration and rapid efficacy of drugs. This technology provides patients with a better treatment experience and strengthens ctcbio's competitiveness in the global market. Our Microbiome Research Institute has developed advanced probiotics for digestive health and immune system enhancement. The developed multi-functional probiotic product contributes to gut health and strengthens the immune system. With its quadruple functionality, this multifunctional product demonstrates our expertise in the health food market. **For animal welfare:** We manufacture and distribute a wide range of veterinary pharmaceuticals, such as antibiotics, coccidiostats, and antipyretic & analgesic medications. Our commitment to high-quality products supports and enhances animal health and sustainable farming. Bacteriophage products are effective animal feed additives that selectively eradicate specific pathogenic bacteria without resistance issues. CTCZYME, the first β-mannanase developed in Asia, is a globally patented enzyme responsible for animal digestion and was selected as a world-class product (Approved by the FDA in 2015, this enzyme enhances nutrient absorption). Those products effectively enhance productivity in livestock. We are continuously expanding our presence in the global market and exploring new possibilities. ctcbio is creating a better tomorrow through innovation.